The choice between one or the other regimen, adding or not chemotherapy to pembrolizumab, must be made carefully by physicians taking into account PS and patient’s choice, beside PD-L1 tumor status and platinum-sensitivity. This evidence concerns the gene CD274 and neoplasm.